Jubilant Pharmova is engaged in specialty pharmaceuticals, CDMO, generics, drug discovery and proprietary novel drug businesses.
In specialty pharmaceuticals, it is the third largest radiopharmaceutical manufacturer with second largest commercial radio pharmacy network in US. It is the second biggest player in the allergenic extract market in the US
In CDMO (CMO, APIs) Jubilant is an integrated contract manufacturer of sterile injectables, ophthalmics, otics and ointments (sterile and non-sterile), creams and liquids
Revenue break up (FY22)- Formulations - 19%, Radiopharma and allergy therapy –43%, CDMO & API – 31% and CRDS – 8%
Q4FY22
Generics and CDMO business were affected leading to reduction in operating leverage this quarter.
Revenues were down 3% YoY to ₹ 1527 crore
EBITDA was at ₹ 247 crore, down 34% YoY with margins at 16.2%
Revenues were at Rs 1,553 crore vs Rs 1,311 crore in Q3FY22 and Rs 1,600 crore in Q2FY23.
Reported EBITDA was at Rs 155 crore vs Rs 200 crore in Q3FY22 and Rs 232 crore in Q2FY23.
In Q3FY23, we witnessed nil COVID-related deals vs Rs 89 crore in Q3FY22 and Rs 22 Crore in Q2FY22.
Finance cost was at Rs 51 crore vs Rs 37 crore in Q3FY22 and Rs 42 crore in Q2FY23. Higher finance cost was on account of the increase in global interest rate benchmarks. 1M SOFR has increased from 3.05% in Q2FY23 to 4.36% in Q3FY23.
Reported PAT was at –ve Rs 16 crore as compared with Rs 51 crore in Q3FY22 and Rs 5 crore in Q2FY23.
EPS was at –ve Rs 0.98 vs. Rs 3.2 in Q3FY22 and Rs 0.34 in Q2FY23.
Capital expenditure for the quarter was Rs 218 crore.
Commenting on Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Pharmova Limited said: “During the quarter, the Company reported higher revenues YoY led by an increase in sales in Radiopharmacies, Allergy and CDMO-API businesses and stable revenues in Radiopharmaceuticals, CDMO Sterile Injectables and Drug Discovery Services businesses.
The company’s profitability stood lower in Q3FY23 vs. YoY and QoQ due to lower Covid-related deals in the CDMO Sterile Injectables business, industry-wide issue of generator supply outage that impacted Radiopharmacies business, lower production in the CDMO-API business and lower volumes in Drug Discovery Services business.
In Generics, the Company has undertaken a large-scale business transformation focused on turnaround through cost optimisations and driving growth in branded markets in India and select international markets.
In FY24, Company’s profitability is expected to improve driven by growth in Radiopharmaceuticals, Allergy Immunotherapy and CDMO Sterile Injectables businesses. Recovery in Generics, API businesses and Radiopharmacies will also contribute to better profitability.
The Company has several growth levers across its various businesses (Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Generics and CRDMO), which shall drive sustainable growth for the company in the medium term. In our Proprietary Novel Drugs business, we have several high potential programs, which are at the preclinical/clinical stage.”
Jubilant Pharma Limited is engaged in the Pharmaceutical sector. The company has its market capitalization worth INR 11,533.55 crore as of 16th April 2021. The company was incorporated in 1978. The company has reported quarterly revenue of INR 828.94 crore at the end of December 2020. This company is listed on the Bombay Stock Exchange (BSE), having the code 530019 and on the National Stock Exchange (NSE) with the symbol JUBLPHARMA.
The company is headquartered in Noida. It is a pharmaceutical company that offers products and services across the pharma value chain that includes manufacturing and supply of Allergy Therapy Products, Active Pharmaceutical Ingredients.
Jubilant Pharmova Limited is a manufacturer and supplier of active pharmaceutical ingredients, radiopharmaceuticals, solid dosage formulations, advanced intermediates, allergy therapy products and nutritional products. It focuses on catering to unmet medical needs at a very affordable price. Pharmaceuticals, contract R&D providers, and patented new products are the company's three market divisions. Via a network of 49 radio pharmacies in the United States, the organisation produces and distributes radiopharmaceuticals. In Bengaluru and Noida, India, it has established two world-class research centres. Shyam S Bhartia, the company's director, oversees procedures.
The company reported record profitability with annual revenue of INR 91544 million during the year, which is up by 0.5% year-on-year. In the same year, the company demerged its LSI (Life Science Ingredients) to create unique entities focused on Pharmaceuticals and LSI businesses. Jubilant Pharmova recorded a splurge of 52% year-on-year growth in quarter three. The CDMO and generics business of the company drove the increase in financials. In 2021, Fitch ratings upgraded Jubilant Pharmova Limited from BB- to BB. The up-gradation is a clear reflection of the improvements in the business profile. As of April 2021, the company announced the completion of safety and absorption studies in healthy human volunteers using a novel oral formulation of Remdesivir. The company entered into a non-exclusive licence agreement with Gilead Sciences Inc., which granted the rights to manufacture register and sell Gilead's Remdesivir in India and 126 other countries. The launch of this oral formulation of Covid medicine is likely to affect the company's growth positively.
Jubilant Pharma Limited is engaged in the Pharmaceutical sector. The company has its market capitalization worth INR 11,533.55 crore as of 16th April 2021. The company was incorporated in 1978. The company has reported quarterly revenue of INR 828.94 crore at the end of December 2020. This company is listed on the Bombay Stock Exchange (BSE), having the code 530019 and on the National Stock Exchange (NSE) with the symbol JUBLPHARMA.
The company is headquartered in Noida. It is a pharmaceutical company that offers products and services across the pharma value chain that includes manufacturing and supply of Allergy Therapy Products, Active Pharmaceutical Ingredients.
Jubilant Pharmova Limited is a manufacturer and supplier of active pharmaceutical ingredients, radiopharmaceuticals, solid dosage formulations, advanced intermediates, allergy therapy products and nutritional products. It focuses on catering to unmet medical needs at a very affordable price. Pharmaceuticals, contract R&D providers, and patented new products are the company's three market divisions. Via a network of 49 radio pharmacies in the United States, the organisation produces and distributes radiopharmaceuticals. In Bengaluru and Noida, India, it has established two world-class research centres. Shyam S Bhartia, the company's director, oversees procedures.
The company reported record profitability with annual revenue of INR 91544 million during the year, which is up by 0.5% year-on-year. In the same year, the company demerged its LSI (Life Science Ingredients) to create unique entities focused on Pharmaceuticals and LSI businesses. Jubilant Pharmova recorded a splurge of 52% year-on-year growth in quarter three. The CDMO and generics business of the company drove the increase in financials. In 2021, Fitch ratings upgraded Jubilant Pharmova Limited from BB- to BB. The up-gradation is a clear reflection of the improvements in the business profile. As of April 2021, the company announced the completion of safety and absorption studies in healthy human volunteers using a novel oral formulation of Remdesivir. The company entered into a non-exclusive licence agreement with Gilead Sciences Inc., which granted the rights to manufacture register and sell Gilead's Remdesivir in India and 126 other countries. The launch of this oral formulation of Covid medicine is likely to affect the company's growth positively.
You can buy Jubilant Pharmova Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Jubilant Pharmova Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Sep 22, 2023 09:49 AM the closing price of Jubilant Pharmova Ltd was ₹ 427.70.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Sep 22, 2023 09:49 AM, the market cap of Jubilant Pharmova Ltd stood at ₹ 6,812.45.
Invest
FAQ’s on Jubilant Pharmova Ltd Shares
